StockData

Aquestive Therapeutics vs ARS Pharmaceuticals

AQST and SPRY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AQST and SPRY compare

Aquestive Therapeutics is the larger company, worth 1.3 times as much as ARS Pharmaceuticals ($464M against $363M).

Aquestive Therapeutics grew revenue faster over the last twelve months (22.6% versus 4.1% for ARS Pharmaceuticals).

Aquestive Therapeutics keeps more of each dollar of sales as profit, with a net margin of −145% compared with −184% at ARS Pharmaceuticals.

ARS Pharmaceuticals scores higher on the StockData Score (8 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAQSTSPRY
Size and price
Market cap$464M$363M
Share price$3.70$3.65
Change, 1 year−31.4%−55.5%
Change, 5 years−41.9%−49.2%
Beta (5Y)1.203.64
Employees147158
StockData Score
Total score38 (better)
Valuation score00
Growth score22
Performance score01 (better)
Health score15 (better)
Dividend score00
Valuation
P/S8.6×3.1× (better)
P/B–29.0×
FCF yield−9.9% (better)−54.2%
Growth
Revenue growth (TTM)22.6% (better)4.1%
Revenue growth, 5Y average−0.58%–
Profitability
Gross margin67.0%–
Operating margin−97.5% (better)−185%
Net margin−145% (better)−184%
FCF margin−85.0% (better)−168%
Return on equity–−210%
Financial health
Debt / equity–0.00
Interest coverage−4.7×–
Current ratio7.19 (better)3.48
Altman Z-score−3.57−3.09 (better)
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions57.4%91.2%
Held by insiders3.2%46.7%
Insider net buying, 12 months−$2.3M−$284K (better)
Superinvestors holding–1
Short interest, % of float24.1%35.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.